Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759928 · ClinicalTrials.gov registry record · Phase 1
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
A Phase 1 study of Refractory Solid Tumors, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT00759928 is a Phase 1 study of Refractory Solid Tumors that has completed, run by SCRI Development Innovations. The registered enrollment target is 48 participants, below the 1,460-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00759928, a Phase 1 study of Refractory Solid Tumors, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
Two cohorts of patients will be enrolled: Cohort A will consist of patients who are current smokers, and Cohort B will consist of patients who are current nonsmokers. There will be 24 patients enrolled in each cohort. Nonsmokers are patients who have not consumed tobacco or nicotine-containing products for 1 year before the start of the study. Patients classified as current smokers must have smoked a minimum of 10 cigarettes per day for up to 1 year. Patients who have smoked 1-9 cigarettes per day for up to 1 year, or more than 10 cigarettes per day for less than 1 year will not be eligible for this study.
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG Erlotinib
Study Locations (2)
Florida
- Florida Cancer Specialists - Fort Myers
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-10 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759928
The ClinicalTrials.gov registry entry for NCT00759928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,460-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (97% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib is the first listed.
NCT00759928 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00759928 about?
NCT00759928 is a clinical study titled "PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors". Two cohorts of patients will be enrolled: Cohort A will consist of patients who are current smokers, and Cohort B will consist of patients who are current nonsmokers. There will be 24 patients enrolled in each cohort. Nonsmokers are patients who have not consumed tobacco or nicotine-containing produ...
What is the current status of trial NCT00759928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-10. Estimated completion is 2014-06.
What conditions does trial NCT00759928 study?
This clinical trial studies the following conditions: Refractory Solid Tumors.
What interventions are being tested in trial NCT00759928?
The interventions under investigation include: Sorafenib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00759928?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00759928 being conducted?
This trial has 2 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RECRUITING · Phase 1
-
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
COMPLETED · Phase 1
-
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
COMPLETED · Phase 1
-
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.